Early and multiple doses of zoledronate mitigates rebound bone loss following withdrawal of RANKL inhibition.
Kim AS, Taylor VE, Castro-Martinez A, Dhakal S, Zamerli A, Mohanty ST, Xiao Y, Simic MK, Pantalone A, Chu J, Cheng TL, Croucher PI, Center JR, Girgis CM, McDonald MM.
Kim AS, et al. Among authors: cheng tl.
J Bone Miner Res. 2025 Jan 23:zjaf008. doi: 10.1093/jbmr/zjaf008. Online ahead of print.
J Bone Miner Res. 2025.
PMID: 39846954